In a reverse IPO Kuros Biosurgery acquired Cytos Biotechnology in January 2016 and subsequently was renamed Kuros Biosciences. Kuros Biosciences focuses on orthobiologics. As of 2017 the company remained headquartered in Switzerland.
Back to overview
